LLY
Eli Lilly and Company
LLY has the edge over VMD overall, supported by stronger fundamentals and stronger modeled upside.
VMD
Viemed Healthcare, Inc.
VMD's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
VMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
VMD's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
VMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $6.92 | -24% |
| Forward | 18x | $9.11 | — |
| Current | 24x | $9.11 | — |
| Fair | 26x | $9.97 | +9.4% |
| Expensive | 36x | $13.67 | +50% |
Historical ranges are pointers, not guarantees.
VMD has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over VMD on the outlook, with more favorable profitability expectations.
VMD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for VMD, with profitability holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over VMD on earnings, with stronger typical year-over-year growth.
VMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.50 | +32% |
| Q3 2026 | $0.38 | +15% |
| Q2 2026 | $0.36 | +5.9% |
| Q1 2026 | $0.37 | +23% |
| Q4 2025 | $0.37 | +32% |
| Q3 2025 | $0.33 | +27% |
| Q2 2025 | $0.34 | +48% |
| Q1 2025 | $0.30 | +20% |
| Q4 2024 | $0.28 | +12% |
VMD's earnings per share have fallen from their peak: $0.38 over the past year, against $0.78 in late 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over VMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over VMD on profitability, with a higher operating margin.
VMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $80.7M | +12% |
| Q2 2026 | $78.1M | +24% |
| Q1 2026 | $75.4M | +28% |
| Q4 2025 | $76.2M | +26% |
| Q3 2025 | $71.9M | +24% |
| Q2 2025 | $63.1M | +15% |
| Q1 2025 | $59.1M | +17% |
| Q4 2024 | $60.7M | +20% |
VMD's revenue has grown year over year for 20 quarters in a row: $81M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.6% | +0.8 points |
| Q2 2026 | 5.7% | -2.4 points |
| Q1 2026 | 5.7% | -0.8 points |
| Q4 2025 | 11% | +0.4 points |
| Q3 2025 | 7.8% | -1.8 points |
| Q2 2025 | 8.1% | +1.5 points |
| Q1 2025 | 6.5% | +2.1 points |
| Q4 2024 | 11% | +0.2 points |
VMD's operating margin was 8.6% last quarter, up 0.8 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over VMD on cash flow, with more consistent year-over-year improvement.
VMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.9M | -73% |
| Q2 2026 | $7.4M | +80% |
| Q1 2026 | $1.4M | +$14M |
| Q4 2025 | $9.7M | +207% |
| Q3 2025 | $10.7M | +516% |
| Q2 2025 | $4.1M | +231% |
| Q1 2025 | -$12.6M | -$7.8M |
| Q4 2024 | $3.2M | -41% |
VMD generated $21M in free cash flow over the past year, about four times what it generated the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over VMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
VMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +66.6K shares |
| 1 year | +1.7% | +697K shares |
| 3 years | +1.9% | +772K shares |
| 5 years | +1.3% | +533K shares |
| Available history | +3.6% | +1.4M shares |
VMD has 41M diluted shares, up 1.7% from a year ago, despite $8M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $977,000 |
| Q2 2026 | $5.3M |
| Q1 2026 | $1.4M |
| Q4 2025 | — |
| Q3 2025 | $11.6M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
VMD spent $8M buying back its own shares over the past year.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
VMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
VMD has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
VMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.9 | Neutral |
| Stochastic | 27.9 | Neutral |
VMD's weekly RSI is 45 (neutral) and its Stochastic is 28 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
VMD PE vs Healthcare Sector
| Metric | VMD | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 26x | 7.3% below |
| PE % | 39 | 29 | 10 pts above |
VMD has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over VMD on trend strength, trading above more of its moving averages.
VMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.34 | 2.5% below |
| 20 week MA | $9.90 | 8% below |
| 50 week MA | $9.25 | 1.5% below |
| 100 week MA | $8.16 | 12% above |
| 200 week MA | $8.23 | 11% above |
VMD has slipped below its 8-, 20- and 50-week averages, though it's still 11% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over VMD on returns for 2026, with the stronger performance.
VMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.28 | $8.00 | +27% |
| 2021 | $8.00 | $5.59 | -30% |
| 2022 | $5.59 | $7.45 | +33% |
| 2023 | $7.45 | $7.85 | +5.4% |
| 2024 | $7.85 | $8.16 | +3.9% |
| 2025 | $8.16 | $7.30 | -11% |
| 2026 YTD | $7.30 | $9.11 | +25% |
VMD has finished higher in four of the last six years. It's up 25% so far in 2026.